Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atamparib - Nerviano Medical Sciences

Next Previous
Drug Profile

Atamparib - Nerviano Medical Sciences

Alternative Names: ONO-7119; RBN-2397

Latest Information Update: 14 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ribon Therapeutics
  • Developer Nerviano Medical Sciences; Ono Pharmaceutical; Ribon Therapeutics
  • Class Amines; Antineoplastics; Ethers; Fluorinated hydrocarbons; Ketones; Piperazines; Pyridazines; Pyrimidines; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase 7 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Adenocarcinoma; Solid tumours; Squamous cell cancer

Most Recent Events

  • 18 Mar 2026 Phase-I/II clinical trials in Adenocarcinoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in China (PO) (NCT07374419)
  • 18 Mar 2026 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in China (PO) (NCT07374419)
  • 04 Feb 2026 Discontinued - Phase-I for Solid tumours (Combination therapy) in Japan (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top